XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company based in Calgary, Alberta, has announced plans to file a Clinical Trial Application (CTA) with Health Canada for its XRx-026 gout program, which features its proprietary XORLO™ oxypurinol formulation. The planned CTA supports the company's two-part clinical study, XRX-OXY-102, and extends its international regulatory strategy beyond its previously announced planned U.S. FDA New Drug Application. Conducting the first part of the study in Canada is expected to accelerate the delivery of key clinical data supporting the FDA filing. Investors may be watching for further updates as the company progresses toward both regulatory submissions.

Key Points

  • XORTX Therapeutics Inc. (NASDAQ: XRTX) is a Calgary-based late-stage clinical pharmaceutical company
  • XORTX has outlined plans for a CTA submission to Health Canada for its XRx-026 gout program featuring XORLO™
  • The Canadian study is intended to run in parallel with the company's planned NDA filing with the U.S. FDA
  • XORTX disclosed increased inquiries from potential commercialization partners but confirmed no agreements have been signed

XORTX Extends XRx-026 Regulatory Strategy into Canada with Health Canada CTA

XORTX announced that its drug development team has been preparing a CTA for filing with Health Canada, describing the clinical development plan for the XRx-026 program and its intention to seek regulatory approval in Canada alongside its planned U.S. FDA NDA filing. The application relates to the planned XRX-OXY-102 clinical study evaluating XORLO™, the company's proprietary formulation of oxypurinol, a xanthine oxidase inhibitor. Part one of the XRX-OXY-102 study builds upon previously reported positive clinical results for the XORLO™ formulation and is designed to further characterise the commercial tablet form.

XORLO™ Designed to Address Unmet Need in Gout Treatment

The XRx-026 program targets patients with hyperuricemia-associated gout, a condition affecting approximately 9.2 million individuals in the United States alone, the release states. Current standard-of-care treatments include allopurinol and febuxostat, though both carry limitations — roughly three to five percent of patients cannot tolerate allopurinol, while febuxostat now carries a cardiovascular risk boxed warning that has substantially reduced its use. XORLO™ is designed to offer a differentiated safety and efficacy profile as an alternative therapeutic option, positioning the company to address a significant unmet clinical need.

Commercialisation Partner Inquiries Rise as XRx-026 Program Advances

As XRx-026 has progressed, XORTX disclosed it has received increased inquiries from potential commercialisation partners across multiple jurisdictions. However, the company confirmed it has not entered into any agreement with any such party and cautioned that there is no assurance that any discussions will result in a transaction. Co-CEO Dr. Allen Davidoff stated in the announcement that approaches making more efficient use of capital, personnel, and time are expected to accelerate XORLO™'s availability to patients globally and enhance the overall value of the XRx-026 program for the company and its shareholders.